Impax Asset Management Group plc Has $14.45 Million Position in Neurocrine Biosciences, Inc. $NBIX

Impax Asset Management Group plc lifted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 15.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 115,000 shares of the company’s stock after purchasing an additional 15,000 shares during the quarter. Impax Asset Management Group plc owned about 0.12% of Neurocrine Biosciences worth $14,454,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in NBIX. IFP Advisors Inc boosted its holdings in shares of Neurocrine Biosciences by 4.2% in the 2nd quarter. IFP Advisors Inc now owns 2,172 shares of the company’s stock valued at $273,000 after buying an additional 88 shares during the last quarter. Linden Thomas Advisory Services LLC increased its holdings in shares of Neurocrine Biosciences by 1.5% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 6,699 shares of the company’s stock worth $842,000 after acquiring an additional 96 shares during the last quarter. DE Burlo Group Inc. raised its stake in Neurocrine Biosciences by 2.2% in the 1st quarter. DE Burlo Group Inc. now owns 4,717 shares of the company’s stock valued at $522,000 after acquiring an additional 100 shares during the period. Central Pacific Bank Trust Division boosted its holdings in shares of Neurocrine Biosciences by 6.2% during the 2nd quarter. Central Pacific Bank Trust Division now owns 1,725 shares of the company’s stock worth $217,000 after buying an additional 100 shares during the period. Finally, AdvisorShares Investments LLC increased its stake in shares of Neurocrine Biosciences by 2.8% during the second quarter. AdvisorShares Investments LLC now owns 3,666 shares of the company’s stock worth $461,000 after purchasing an additional 100 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Kyle Gano sold 300 shares of the firm’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00. Following the transaction, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at $19,933,581.79. This trade represents a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William H. Rastetter sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total value of $2,732,760.00. Following the completion of the transaction, the director owned 40,360 shares in the company, valued at $6,127,455.20. The trade was a 30.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Stock Down 1.8%

Shares of NBIX opened at $144.16 on Friday. The business’s fifty day moving average is $142.63 and its 200 day moving average is $132.42. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $157.67. The stock has a market cap of $14.37 billion, a P/E ratio of 34.49, a P/E/G ratio of 0.94 and a beta of 0.22.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, October 28th. The company reported $2.17 EPS for the quarter, topping the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The company had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. During the same period in the previous year, the firm posted $1.81 earnings per share. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. On average, analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

NBIX has been the subject of several analyst reports. UBS Group lifted their price objective on shares of Neurocrine Biosciences from $188.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Citigroup increased their target price on Neurocrine Biosciences from $175.00 to $203.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Wednesday, October 8th. Wall Street Zen raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Finally, Needham & Company LLC boosted their target price on Neurocrine Biosciences from $170.00 to $184.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.53.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.